A clinical trial of SLC26A4 mutation-induced hearing loss was suggested with a cochlear implant [138], whereas the studies of SLC26A4-related disease treatment are restricted to gene delivering therapy. The gene discussed is SLC26A4; the disease is hearing loss disorder.